GlassScriptPhysician profile
Edwin Mejia Ortega
NPI 1164909149
$14,252.42
in general payments reported to CMS, 2019-2025
24 companies · $3,089 in 2025
The $3,089 reported for 2025 was more than what 99% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
See the full distribution for Pediatrics (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $360 · 2022: $739 · 2023: $7,940 · 2024: $2,124 · 2025: $3,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,843 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,260 · Travel and Lodging: $1,050 · Consulting Fee: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,843.07 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,260.29 |
| Travel and Lodging | $1,049.81 |
| Consulting Fee | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $3,997.16 | 2023-2025 | Crysvita |
| Medtronic, INC. | $3,954.89 | 2021-2023 | Minimed 780g, Minimed 770g |
| Genzyme Corporation | $1,149.59 | 2025 | |
| Insulet Corporation | $936.16 | 2023-2025 | Omnipod, Omnipod |
| Ascendis Pharma Endocrinology INC | $543.71 | 2022-2025 | Skytrofa, Yorvipath |
| Novo Nordisk INC | $519.58 | 2023-2025 | Sogroya |
| Sanofi-Aventis U.S. LLC | $513.81 | 2023-2025 | |
| Tandem Diabetes Care, INC. | $435.19 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $282.89 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Tolmar, INC. | $265.99 | 2023-2025 | Fensolvi |
| Azurity Pharmaceuticals, INC. | $245.10 | 2023-2025 | Triptodur, Triptodur |
| Neurocrine Biosciences, INC. | $244.46 | 2024-2025 | |
| Abbott Laboratories | $231.98 | 2023-2025 | Freestyle Libre, Freestyle Libre 3 |
| Dexcom, INC. | $203.00 | 2022-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $150.12 | 2021-2025 | Gvoke Hypopen |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $144.83 | 2023-2025 | |
| Abbvie INC. | $90.55 | 2023-2025 | |
| Endo USA, INC. | $88.23 | 2024-2025 | Supprelin |
| Eton Pharmaceuticals, INC. | $82.91 | 2023-2025 | Alkindi, Increlex, Khindivi |
| Endo Pharmaceuticals INC. | $58.61 | 2021-2024 | Supprelin |
| Biomarin Pharmaceutical INC. | $55.72 | 2024 | Voxzogo 1.2mg |
| Sequel Med Tech, LLC | $21.44 | 2025 | Twiist |
| Tolmar Pharmaceuticals, INC. | $19.36 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $17.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Mejia Ortega listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.